CUREXO. Company Introduction, Items, Products, Trading Volume, Stock Outlook, News, Supply, Contract, Development, Cooperation, Government Policy, Government Project, Stock Theme, Reason for Stock Rise Today, 2026 Outlook Scenario
CUREXO is a representative Korean medical robotics company that has been leading the surgical and rehabilitation robot market based on its unique robotics technology since its establishment in 1992. It inherited the ROBODOC technology by acquiring the assets of ISS in the US and is currently accelerating its global market penetration through its own brand, the CUVIS series. Its largest shareholder is hy (formerly Korea Yakult), ensuring a stable governance structure for continuous R&D investment.
.
.
Items and Products
The main product line consists of the CUVIS-joint for artificial joint surgery, the CUVIS-spine for spinal surgery, and the Morning Walk S200 for gait rehabilitation. Specifically, the CUVIS-joint is an 'Active' robot that senses the patient's condition in real-time, with AI creating an optimal surgical plan for precise execution, boasting high accuracy in knee and hip replacement surgeries. It also holds a diverse lineup of medical devices, including the InMotion upper limb rehabilitation robot.
.
.
Trading Volume
Recently, CUREXO's trading volume has shown increased volatility following expectations for US FDA approval and participation in global conferences. During periods of high interest in the medical robot sector, institutional and foreign capital often concentrates, leading to mass trading several times higher than the average volume. This indicates that the market highly values CUREXO's technical prowess and overseas expansion potential.
.
.
Stock Outlook
Securities analysts expect CUREXO's growth value to enter a full-scale earnings turnaround starting from 2025. Following a successful settlement in the Indian market, a re-rating of corporate value is expected when the licensing in the US and European markets, the world's largest medical device markets, is finalized. The establishment of a 'recurring revenue model' through consumables and service sales will be the key driver for the stock price.
.
.
News
According to recent news, CUREXO participated in 'AAOS 2026', the world's largest orthopedic conference held in New Orleans, successfully showcasing its AI-based automatic bone segmentation technology and CUVIS-joint products. Reports continue to highlight the company's focus on developing products for the North American market and securing distribution networks through cooperation with US investment firm THINK Surgical.
.
.
Supply and Contract
CUREXO has rapidly expanded its market share in India by signing a large-scale supply contract with Meril Healthcare, a major Indian hospital chain and medical device distributor. For the US market, it has an exclusive supply and distribution agreement for the CUVIS-joint through THINK Surgical, with full-scale supply expected to commence following FDA approval. Domestically, it consistently supplies robot systems to numerous university and specialized hospitals.
.
.
Development and Cooperation
The company is dedicated to developing technology to implement the 'Physical AI' concept in medical fields, centered on its R&D staff of about 50 experts. It is co-developing a next-generation surgical robot platform with THINK Surgical and conducting clinical research and national projects with major Korean medical institutions such as Samsung Medical Center and Severance Hospital.
.
.
Government Policy and Project
In line with the government's policy to foster the bio-health and robot industries, CUREXO has obtained innovative medical device certification and carried out various national projects. It participates as a lead agency in AI-based medical robot development and intelligent rehabilitation robot distribution projects, receiving government support to enhance technical competitiveness for exports.
.
.
Stock Theme
Major stock themes include Medical Robots, Intelligent Robots, AI Healthcare, and the Silver Industry (Rehabilitation). It is often grouped as a beneficiary when global big tech firms like NVIDIA invest in medical AI and shows movements as a leader in the robot sector in connection with large corporations' entry into the industry.
.
.
Reason for Stock Rise Today
**Acceleration of Earnings Turnaround: **
Expectations for earnings improvement due to increased medical robot sales followed the previous quarter's operating profit turnaround. Additionally, the successful technology demonstration at major US conferences and the visualized FDA approval roadmap for the CUVIS-joint scheduled for the first half of 2026 led to preemptive buying.
.
.
3. Technical Analysis and Supply-Demand Status
Technically, the stock is maintaining an upward trend by breaking through major resistance levels, with steady net buying from foreign and institutional investors adding stability. The powerful momentum of accelerating global market entry is driving the price.
.
.
2026 Outlook Scenario
2026 is expected to be the year CUREXO completes its global leap. In a positive scenario, the US FDA approval for the CUVIS-joint will be finalized in the first half, leading to exponential revenue growth in the North American market. Furthermore, based on obtaining the European CE certification, its entry into the European market will become full-scale, and with an increased share of recurring revenue from consumables, the operating margin is projected to improve to over 15%, solidifying its position as a global medical robot specialist.